News in the systemic Therapy of gynecological Malignancies 2020-2022

Greil-Ressler, S ONCOL RES TREAT. 2022; 45(SUPPL 2): 179-179.

Prognostic and predictive value of 18F-FDG PET/CT in assessment of treatment response and PFS in gastric cancer patient underwent neoadjuvant chemotherapy using FLOT regimen

Seyedinia, S; Huemer, F; Mirshahvalad, S; Koch, O; Weiss, L; Emmanuel, K; Pirich, C; Greil, R; Beheshti, M EUR J NUCL MED MOL I. 2022; 49(SUPPL 1): S473-S473.

A CD73 ENZYME ACTIVITY ASSAY FOR STABILITY AND DOSE-FINDING OF THERAPEUTICALLY-ACTIVE EVS

Arzt, C; Fang, H; Grasmann, E; Kals, C; Bayer, E; Auer, D; Schally, T; Rohde, E; Gimona, M CYTOTHERAPY. 2022; 24(5): S89-S89.

Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study

Dietrich, S; Tilly, H; Morschhauser, F; Sehn, LH; Friedberg, JW; Trneny, M; Sharman, J; Herbaux, C; Burke, JM; Matasar, M; Rai, S; Izutsu, K; Mehta-Shah, N; Oberic, L; Chauchet, A; Jurczak, W; Song, YQ; Greil, R; Mykhalska, L; Burgues, JMB; Cheung, MC; Pinto, A; Shin, HJ; Hapgood, G; Munhoz, E; Salles, G ONCOL RES TREAT. 2022; 45(SUPPL 3): 165-165.

Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)

Luftner, D; Bartsch, R; Breitenstein, U; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Schwitter, M; Zaman, K; Wrobel, D; Guth, D; Terhaag, J; Zaiss, M; Distelrath, A; Lorenz, A; Schinkothe, T; Harbeck, N ONCOL RES TREAT. 2022; 45(SUPPL 3): 20-21.

Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: a multi-centric, multi-national, prospective, non-interventional study in Germany, Austria and Switzerland – BERING CRC

Prager, G; Hubner, G; Schroder, J; Forstbauer, H; Kisro, J; Welslau, M; Burkle, D; Von der Heyde, E; Muller-Huesmann, H; Krammer-Steiner, B; Hering-Schubert, C; Popper, U; Gerger, A; Greil, R; Reichenbach, F; Arnold, D; Fritsch, R; Hegewisch-Becker, S; Vogel, A; Wagner, AD; Winder, T; Koeberle, D; Stintzing, S ONCOL RES TREAT. 2022; 45(SUPPL 3): 64-64.

Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

Machiels, JP; Tao, Y; Burtness, B; Tahara, M; Rischin, D; Alves, GV; Lima, IPF; Hughes, BGM; Pointreau, Y; Aksoy, S; Laban, S; Greil, R; Burian, M; Hetnal, M; Licitra, LF; Swaby, R; Zhang, Y; Gumuscu, B; Bidadi, B; Siu, LL ANN ONCOL. 2022; 33(7): S1399-S1399.

Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048

Tahara, M; Greil, R; Rischin, D; Harrington, KJ; Burtness, B; De Castro, G; Psyrri, A; Brana, I; Neupane, P; Bratland, A; Fuereder, T; Hughes, BGM; Nin, RM; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Lin, J; Gumuscu, B; Lerman, N; Soulieres, D ANN ONCOL. 2022; 33(7): S844-S844.

Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study

Yu, EY; Park, SH; Goh, JCH; Shin, SJ; Mehra, N; McDermott, R; Gonzalez, MAS; Fong, PC; Greil, R; Retz, M; Sade, JP; Huang, YH; Begbie, S; Rey, F; Kramer, G; Suzuki, H; Zhang, J; Kim, J; Poehlein, CH; Antonarakis, ES ANN ONCOL. 2022; 33(7): S1163-S1164.

PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial by the German Hodgkin Study Group

Jacob, AS; Fuchs, M; Kaul, H; Kobe, C; Pabst, T; Greil, R; Eichenauer, D; Topp, M; Just, M; Hertenstein, B; Schaub, V; Vogelhuber, M; Zijlstra, JM; Pluetschow, A; Baues, C; Rosenwald, A; Dietlein, M; Borchmann, P; Engert, A ONCOL RES TREAT. 2022; 45(SUPPL 3): 168-168.